The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Open accessAbstract
Multidrug resistance (MDR) is a major cause of failure in cancer chemotherapy. P-glycoprotein (P-gp), a promiscuous drug efflux pump, has been extensively studied for its association with MDR due to overexpression in cancer cells. Several P-gp inhibitors or modulators have been investigated in clinical trials in hope of circumventing MDR, with only limited success. Alternative strategies are actively pursued, such as the modification of existing drugs, development of new drugs, or combination of novel drug delivery agents to evade P-gp-dependent efflux. Despite the importance and numerous studies, these efforts have mostly been undertaken without a priori knowledge of how drugs interact with P-gp at the molecular level. This review highlights and discusses progress toward and challenges impeding drug development for inhibiting or evading P-gp in the context of our improved understanding of the structural basis and mechanism of P-gp-mediated MDR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“pivotal role in normal physiological detoxification and host protection processes by transporting numerous exogenous and endogenous substrates.(2) P-gp is distributed in the”
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Self-citationCordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., & Rothbard, J. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13003 · Cited by 1,615
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Structure of a bacterial multidrug ABC transporter
Dawson, R. J. P., & Locher, K. P. (2006) · Nature · doi:10.1038/nature05155 · Cited by 1,279
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Flexibility in the ABC transporter MsbA: Alternating access with a twist
Ward, A., Reyes, C. L., Yu, J., Roth, C. B., & Chang, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709388104 · Cited by 771
Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von Hoff, D. D., et al. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7160 · Cited by 714
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“It was approved by the FDA as a second-line treatment for metastatic breast cancer.(108) Other drug-polymer conjugates with cytotoxic drugs have also been”
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685
ABC Efflux Pump-Based Resistance to Chemotherapy Drugs
Eckford, P. D. W., & Sharom, F. J. (2009) · Chemical Reviews · doi:10.1021/cr9000226 · Cited by 597
The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein research
Gottesman, M. M., & Ling, V. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.060 · Cited by 558
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
Positively Cooperative Sites for Drug Transport by P‐Glycoprotein with Distinct Drug Specificities
Shapiro, A. B., & Ling, V. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00130.x · Cited by 475
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., & Gabizón, A. (2000) · PubMed · Cited by 468
Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans
Jin, M. S., Oldham, M. L., Zhang, Q., & Chen, J. (2012) · Nature · doi:10.1038/nature11448 · Cited by 465
Self-citationLee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453
List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 419
Communication between Multiple Drug Binding Sites on P-glycoprotein
Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., & Callaghan, R. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12429-7 · Cited by 418
Structure of the human multidrug transporter ABCG2
Taylor, N. M. I., Manolaridis, I., Jackson, S. M., Kowal, J., Stahlberg, H., & Locher, K. P. (2017) · Nature · doi:10.1038/nature22345 · Cited by 418
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · cited 1×
“For example, SP1049C is a P-gp targeting non-ionic blockcopolymer formulation containing doxorubicin as the cytotoxic payload.(104) SP1049C has”
Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1
Johnson, Z. L., & Chen, J. (2017) · Cell · doi:10.1016/j.cell.2017.01.041 · Cited by 375
Stanzl, E. G., Trantow, B. M., Vargas, J. R., & Wender, P. A. (2013) · Accounts of Chemical Research · doi:10.1021/ar4000554 · Cited by 345
Refined structures of mouse P‐glycoprotein
Li, J., Jaimes, K. F., & Aller, S. G. (2014) · Protein Science · doi:10.1002/pro.2387 · Cited by 344
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
Dey, S., Ramachandra, M., Pastan, I., Gottesman, M. M., & Ambudkar, S. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10594 · Cited by 330
Shapiro, A. B., Fox, K., Lam, P., & Ling, V. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00098.x · Cited by 304
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Wong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., Erhan, S. Z., & Wu, X. Y. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0282-x · Cited by 303
Sharom, F. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00041 · Cited by 278
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Drug resistance: Still a daunting challenge to the successful treatment of AML
Shaffer, B. C., Gillet, J.-P., Patel, C., Baer, M. R., Bates, S. E., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.001 · Cited by 259
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
Ward, A. B., Szewczyk, P., Grimard, V., Lee, C.-W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309275110 · Cited by 256
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Dubikovskaya, E. A., Thorne, S. H., Pillow, T. H., Contag, C. H., & Wender, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805374105 · Cited by 249
Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein
Verhalen, B., Dastvan, R., Thangapandian, S., Peskova, Y., Koteiche, H. A., Nakamoto, R. K., Tajkhorshid, E., & Mchaourab, H. S. (2017) · Nature · doi:10.1038/nature21414 · Cited by 248
Larson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T., & Bates, S. E. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.002 · Cited by 219
Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S., & Fojo, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117910 · Cited by 216
Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 213
Lindgren, M., Rosenthal-Aizman, K., Saar, K., Eiríksdóttir, E., Jiang, Y., Sassian, M., Östlund, P., Hällbrink, M., & Langel, Ü. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.048 · Cited by 207
Tumor heterogeneity and drug resistance.
Dexter, D. L., & Leith, J. T. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.244 · Cited by 206
Sears, J. E., & Boger, D. L. (2015) · Accounts of Chemical Research · doi:10.1021/ar500400w · Cited by 201
Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., & Benoît, J.-P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0289 · Cited by 198
Altmann, K.-H., Wartmann, M., & O’Reilly, T. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00009-3 · Cited by 191
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
The Biology and Medicinal Chemistry of Epothilones
Wartmann, M., & Altmann, K. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354489 · Cited by 182
Esser, L., Zhou, F., Pluchino, K. M., Shiloach, J., Ma, J., Tang, W.-K., Gutierrez, C., Zhang, A., Shukla, S., Madigan, J. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755884 · Cited by 182
Kannan, P., Telu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Halldin, C., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn100078a · Cited by 181
Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein
Szewczyk, P., Tao, H., McGrath, A. P., Villaluz, M., Rees, S. D., Lee, S. C., Doshi, R., Urbatsch, I. L., Zhang, Q., & Chang, G. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715000978 · Cited by 180
Self-citationPolymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
Duncan, R., Vicent, M. J., Greco, F., & Nicholson, R. I. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01045 · Cited by 179
P-glycoprotein ABCB1: a major player in drug handling by mammals
Borst, P., & Schinkel, A. H. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70430 · Cited by 167
Naito, K., Takeshita, A., Shigeno, K., Nakamura, S., Fujisawa, S., Shinjo, K., Yoshida, H., Ohnishi, K., Mori, M., Terakawa, S., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401851 · Cited by 153
Tenuecyclamides A−D, Cyclic Hexapeptides from the Cyanobacterium Nostoc spongiaeforme var. tenue
Banker, R., & Carmeli, S. (1998) · Journal of Natural Products · doi:10.1021/np980138j · Cited by 152
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
Singer, J. W., Shaffer, S. A., Baker, B., Bernareggi, A., Stromatt, S. C., Nienstedt, D., & Besman, M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200503000-00003 · Cited by 149
DAMASCELLI, B., Cant�, G., Mattavelli, F., Tamplenizza, P., Bidoli, P., Leo, E., Dosio, F., Cerrotta, A., Tolla, G. D., Frigerio, L. F., et al. (2001) · Cancer · Cited by 146
Ogino, J., Moore, R. E., Patterson, G. M. L., & Smith, C. D. (1996) · Journal of Natural Products · doi:10.1021/np960178s · Cited by 140
Aroui, S., Brahim, S., WAARD, M. M. D., & Kénani, A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.073 · Cited by 132
Duncan, R., Ringsdorf, H., & Satchi‐Fainaro, R. (2006) · Journal of drug targeting · doi:10.1080/10611860600833856 · Cited by 132
Höll, V., Kouba, M., Dietel, M., & Vogt, G. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90149-d · Cited by 131
McKinlay, C. J., Waymouth, R. M., & Wender, P. A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b13452 · Cited by 130
Distinct Conformational Spectrum of Homologous Multidrug ABC Transporters
Moeller, A., Lee, S. C., Tao, H., Speir, J. A., Chang, G. A., Urbatsch, I. L., Potter, C. S., Carragher, B. O., & Zhang, Q. (2015) · Structure · doi:10.1016/j.str.2014.12.013 · Cited by 129
Self-citationAbidi, A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119704 · Cited by 122
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kamath, A. V., Smykla, R. A., Kramer, R. A., & Vite, G. D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0724-8 · Cited by 121
Regulations of P-Glycoprotein/ABCB1/MDR1in Human Cancer Cells
Katayama, K., Noguchi, K., & Sugimoto, Y. (2014) · New Journal of Science · doi:10.1155/2014/476974 · Cited by 118
Bai, J., Swartz, D. J., Protasevich, I. I., Brouillette, C. G., Harrell, P. M., Hildebrandt, E. F., Gasser, B., Mattanovich, D., Ward, A. B., Chang, G. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022577 · Cited by 114
Maderna, A., & Leverett, C. A. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500762u · Cited by 108
P-glycoprotein Inhibition: The Past, the Present and the Future
Darby, R. A. J., Callaghan, R., & McMahon, R. M. (2011) · Current Drug Metabolism · doi:10.2174/138920011798357006 · Cited by 101
Mechanisms of Resistance to Cabazitaxel
Durán, G. E., Wang, Y. C., Francisco, E. B., Rose, J. C., Martinez, F. J., Coller, J., Brassard, D., Vrignaud, P., & Sikic, B. I. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0155 · Cited by 100
Alakhova, D. Y., Zhao, Y., Li, S., & Kabanov, A. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072238 · Cited by 91
Structure of a multidrug transporter
Gottesman, M. M., Ambudkar, S. V., & Xia, D. (2009) · Nature Biotechnology · doi:10.1038/nbt0609-546 · Cited by 89
New Cyclic Peptides from the AscidianLissoclinumpatella
Fu, X., Do, T., Schmitz, F. J., Andrusevich, V. E., & Engel, M. H. (1998) · Journal of Natural Products · doi:10.1021/np9802872 · Cited by 89
Loo, T. W., & Clarke, D. M. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00165-0 · Cited by 86
Frank, G. A., Shukla, S., Rao, P., Borgnia, M. J., Bartesaghi, A., Merk, A., Mobin, A., Esser, L., Earl, L. A., Gottesman, M. M., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104190 · Cited by 83
Bistratamides E−J, Modified Cyclic Hexapeptides from the Philippines Ascidian Lissoclinum bistratum
Perez, L. J., & Faulkner, D. J. (2003) · Journal of Natural Products · doi:10.1021/np0204601 · Cited by 82
Vredenburg, M., Ojima, I., Veith, J. M., Pera, P. J., Kee, K., Cabral, F., Sharma, A. B., Kanter, P. M., Greco, W. R., & Bernacki, R. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1234 · Cited by 81
The Remarkable Transport Mechanism of P-Glycoprotein: A Multidrug Transporter
Al‐Shawi, M. K., & Omote, H. (2005) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-005-9497-5 · Cited by 79
Abbasi, M., Lavasanifar, A., & Uludaˇ, H. (2011) · Medicinal Research Reviews · doi:10.1002/med.20244 · Cited by 73
Vargas, J. R., Stanzl, E. G., Teng, N. N. H., & Wender, P. A. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500161z · Cited by 72
Huang, Y., Cole, S. P. C., Cai, T., & Cai, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4596 · Cited by 72
Etiévant, C., Barret, J.-M. M., Kruczynski, A., Perrin, D., & Hill, B. T. (1998) · Investigational New Drugs · doi:10.1023/a:1006022811895 · Cited by 71
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein
Weidner, L. D., Fung, K.-L., Kannan, P., Moen, J. K., Kumar, J. S., Mulder, J., Innis, R. B., Gottesman, M. M., & Hall, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067785 · Cited by 70
Loo, T. W., Bartlett, M. C., Detty, M. R., & Clarke, D. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.376202 · Cited by 66
Loo, T. W., & Clarke, D. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.006 · Cited by 58
Cabazitaxel, a new taxane with favorable properties
Bouchet, B. P., & Galmarini, C. M. (2010) · Drugs of today · doi:10.1358/dot.2010.46.10.1519019 · Cited by 56
Barker, T. J., Duncan, K. K., Otrubova, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400281w · Cited by 55
van Tellingen, O., Buckle, T., Jonker, J. W., van der Valk, M. A., & Beijnen, J. H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601363 · Cited by 54
Tang, R., Cohen, S., Perrot, J., Faussat, A., Zuany‐Amorim, C., Marjanovic, Z., Morjani, H., Fava, F., Corre, E., Legrand, O., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-199 · Cited by 50
A reciprocating twin-channel model for ABC transporters
Jones, P. M., & George, A. M. (2014) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583514000031 · Cited by 43
RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.
Slate, D. L., Bruno, N. A., Casey, S., Zutshi, N., Garvin, L. J., Wu, H., & PFISTER, J. R. (1995) · PubMed · Cited by 41
Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma
Wender, P. A., Galliher, W. C., Bhat, N. M., Pillow, T. H., Bieber, M. M., & Teng, N. N. H. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.049 · Cited by 39
Ferlini, C., Distefano, M., Pignatelli, F., Lin, S., Riva, A., Bombardelli, E., Mancuso, S., Ojima, I., & Scambia, G. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1500 · Cited by 39
Emmert, D., Campos, C. R., Ward, D., Lu, P., Namanja-Magliano, H. A., Bohn, K. C., Miller, D. S., Sharom, F. J., Chmielewski, J. A., & Hrycyna, C. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn4002329 · Cited by 32
Carney, D. W., Lukesh, J. C., Brody, D. M., Brütsch, M. M., & Boger, D. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611405113 · Cited by 29
Design and Synthesis of Selenazole‐Containing Peptides for Cocrystallization with P‐Glycoprotein
Tao, H., Weng, Y., Zhuo, R., Chang, G. A., Urbatsch, I. L., & Zhang, Q. (2011) · ChemBioChem · doi:10.1002/cbic.201100048 · Cited by 24
Self-citationPluchino, K. M., Hall, M. D., Moen, J. K., Chufán, E. E., Fetsch, P. A., Shukla, S., Gill, D. R., Hyde, S. C., Xia, D., Ambudkar, S. V., et al. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01064 · Cited by 17
Bohn, K. C., Lange, A., Chmielewski, J. A., & Hrycyna, C. A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01044 · Cited by 17
Resistance to Differentiation Therapy
Özpolat, B. (2009) · Springer eBooks · doi:10.1007/978-0-387-89445-4_10 · Cited by 4
Cited by
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
McLoughlin, E. C., & O’Boyle, N. M. (2020) · Pharmaceuticals · doi:10.3390/ph13010008 · Cited by 316
Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance
Xiao, H., Zheng, Y., Ma, L., Tian, L., & Sun, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648407 · Cited by 263
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Metadata
- Authors
- Waghray, D., & Zhang, Q.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-12-18
- Volume
- 61
- Issue
- 12
- Pages
- 5108-5121
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2779730509
- Cited by
- 400
- References
- 118
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.